Evidence map›Paper›PMID 25535727›Full record

ArticleBritish journal of cancer2015

MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.

J Cebulla, E M Huuse, K Pettersen, A van der Veen, E Kim, S Andersen, W S Prestvik, A M Bofin, A P Pathak, G Bjørkøy and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Feasibility and utility of MRI and dynamicJournal of translational medicine · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

J CebullaDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim 7491, Norway.
E M Huuse1] Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim 7491, Norway [2] Department of Medical Imaging, St Olavs University Hospital, Trondheim 7006, Norway.
K Pettersen1] Center of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway [2] Department of Technology, University College of Sør-Trøndelag, Trondheim 7006, Norway [3] Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim 7006, Norway.
A van der VeenCenter of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway.
E KimDepartment of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
S Andersen1] Center of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway [2] Department of Technology, University College of Sør-Trøndelag, Trondheim 7006, Norway.
W S PrestvikDepartment of Technology, University College of Sør-Trøndelag, Trondheim 7006, Norway.
A M BofinDepartment of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim 7006, Norway.
A P PathakRussell H Morgan Department of Radiology and Radiological Science and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
G Bjørkøy1] Center of Molecular Inflammation Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491, Norway [2] Department of Technology, University College of Sør-Trøndelag, Trondheim 7006, Norway.
T F BathenDepartment of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim 7491, Norway.
S A Moestue1] Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim 7491, Norway [2] Department of Medical Imaging, St Olavs University Hospital, Trondheim 7006, Norway.
Norwegian University of Science and Technology · NOJohns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USSt Olav's University Hospital · NOTrønderEnergi (Norway) · NO

Funding

Multiscale Image-based Modeling of Antiangiogenic Resistance in Breast CancerR01CA196701 · NCI · JOHNS HOPKINS UNIVERSITY · PI Arvind P Pathak · 2015 to 2026
$3.6M
NCI NIH HHS R01 CA196701
6 · The paper itself

Abstract

backgroundThe phosphoinositide-3 kinase (PI3K) pathway is an attractive therapeutic target. However, difficulty in predicting therapeutic response limits the clinical implementation of PI3K inhibitors. This study evaluates the utility of clinically relevant magnetic resonance imaging (MRI) biomarkers for noninvasively assessing the in vivo response to the dual PI3K/mTOR inhibitor BEZ235 in two ovarian cancer models with differential PI3K pathway activity.

methodsThe PI3K signalling activity of TOV-21G and TOV-112D human ovarian cancer cells was investigated in vitro. Cellular and vascular response of the xenografts to BEZ235 treatment (65 mg kg(-1), 3 days) was assessed in vivo using diffusion-weighted (DW) and dynamic contrast-enhanced (DCE)-MRI. Micro-computed tomography was performed to investigate changes in vascular morphology.

resultsThe TOV-21G cells showed higher PI3K signalling activity than TOV-112D cells in vitro and in vivo. Treated TOV-21G xenografts decreased in volume and DW-MRI revealed an increased water diffusivity that was not found in TOV-112D xenografts. Treatment-induced improvement in vascular functionality was detected with DCE-MRI in both models. Changes in vascular morphology were not found.

conclusionsOur results suggest that DW- and DCE-MRI can detect cellular and vascular response to PI3K/mTOR inhibition in vivo. However, only DW-MRI could discriminate between a strong and weak response to BEZ235.

Indexed as

Magnetic Resonance ImagingAnimalsAntineoplastic AgentsFemaleHumansImidazolesMiceMice, Inbred BALB CMice, NudeNeovascularization, PathologicOvarian NeoplasmsPhosphatidylinositol 3-KinasesQuinolinesSignal TransductionTreatment OutcomeTumor Cells, CulturedAntineoplastic AgentsdactolisibImidazolesPhosphatidylinositol 3-KinasesQuinolines

Identifiers

PMID25535727
PMCPMC4453650
OpenAlexW2063297982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.